Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Arcus, Ascentage, Beigene, Klotho, Merck, Moderna, Taiho, Transcend.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Astrazeneca, Beone, Biocytogen, Eolas, Secarna, Vect-Horus.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Astellas, Mereo, Osivax, PDS, Pfizer, Tonix, Ultragenyx.
Biopharma dealmaking in June 2025 reached $35.07 billion, the highest monthly total of the year so far and one of the strongest single-month performances in recent years. The June surge helped push first-half 2025 deal value to $138.31 billion, outpacing the first half of 2024 and exceeding full-year totals from several pre-2020 years.
Roche AG subsidiary Chugai Pharmaceutical Co. Ltd. and Singapore’s Gero Pte. Ltd. plan to tackle age-related diseases by collaborating to identify drug targets through Gero’s AI-driven human data-first platform.
RSS
